Zepbound was approved by the Food and Drug Administration in November 2023 for weight loss in adults with obesity or who are overweight with at least one related condition like type 2 diabetes, high cholesterol, or high blood pressure)
Donde el Tirzepatide super la barrera del 20% de prdida de peso combinando la activacin del receptor GLP-1 y el receptor GIP, el Retatrutide va un paso ms all activa simultneamente tres receptores metablicos: GLP-1, GIP y glucagn
Clinical trials typically start at 1mg or 2mg weekly
Weight loss typically plateaus after 12 to 18 months, but this reflects reaching a new metabolic equilibrium rather than medication failure
Biochem 214 , 829835 (1993)
They enable monitoring of GLP-1R activation through SEAP reporter activity, offering a reliable colorimetric incretin bioassay